# PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients

**Status:** RECRUITING

## Eligibility Criteria

**Age:** 18 years and over

This study is NOT accepting healthy

**Healthy Volunteers:** volunteers

**Inclusion Criteria:**

* Patient is willing and able to give informed consent for participation in the study * Patient is aged 18 years or older at the time of consent * Patients undergoing planned breast conserving surgery (for example, lumpectomy or partial mastectomy) and SLNB with Magtrace

---

**Exclusion Criteria:**

* The patient is pregnant or lactating * The patient has had prior breast radiation to the ipsilateral breast * The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes * The patient has recevied a Feraheme (ferumoxytol) injection within the past 6 months * The patient has intolerance or hypersensitivity to iron or dextran compounds or to Magtrace * The patient has iron overload disease * The patient has discoloration on the breast (such as tattoo, birthmark, tanning, rash etc.), that in the Investigator's opinion, could impact the clinical trial results, specifically the assessment of any skin discoloration, or plans to have a tattoo on the breast post-operatively.

## Conditions & Interventions

**Conditions:**
Breast Cancer
**Keywords:**
Magtrace, Sentinel Lymph Node Biopsy

## More Information

**Contact(s):** Vicky Crawford - vcrawford@endomag.com
**Principal Investigator:**
**Phase:**
**IRB**
**Number:**
**System ID:** NCT06610539

---